GLP1R and depressive symptom measurement: Following the opening of the European Medicines Agency (EMA) inquiry in July 2023, numerous epidemiological studies have been examining the risk of depression, suicide, or self-harm associated with GLP1-RAs, leading to conflicting results over short follow-ups.